SCHEMBL1154015

SCHEMBL1154015

OC12CC3C[C@H](C1)C(Nc1ccnc4[nH]ccc14)[C@@H](C3)C2

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 11/20 0.60
▸ JAK1 P23458 11/20 0.60
▸ JAK3 P52333 8/20 0.60
▸ TYK2 P29597 6/20 0.60
▸ HSD11B1 P28845 5/20 0.41
▸ PRKCI P41743 3/20 0.38
▸ ROCK2 O75116 2/20 0.38
▸ ROCK1 Q13464 2/20 0.38
▸ PLK4 O00444 1/20 0.38
▸ PDPK1 O15530 1/20 0.38
▸ RPS6KA5 O75582 1/20 0.38
▸ PRKD3 O94806 1/20 0.38
▸ PAK4 O96013 1/20 0.38
▸ PRKCG P05129 1/20 0.38
▸ CDK1 P06493 1/20 0.38
▸ PRKACA P17612 1/20 0.38
▸ RPS6KB1 P23443 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ LTK P29376 1/20 0.38
▸ AKT1 P31749 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1154014 1.00 JAK2 (0.60) JAK2JAK1JAK3TYK2HSD11B1
SCHEMBL1154013 1.00 JAK2 (0.60) JAK2JAK1JAK3TYK2HSD11B1
SCHEMBL12888143 1.00 JAK2 (0.60) JAK2JAK1JAK3TYK2HSD11B1
SCHEMBL12876314 0.86 JAK2 (0.46) JAK2JAK1JAK3TYK2PRKCI
SCHEMBL12888823 0.80 JAK1 (0.72) JAK2JAK1JAK3TYK2HSD11B1
SCHEMBL12876652 0.79 JAK1 (0.70) JAK2JAK1JAK3TYK2HSD11B1
SCHEMBL27726580 0.79 JAK1 (0.70) JAK2JAK1JAK3TYK2HSD11B1
SCHEMBL12876688 0.79 JAK1 (0.70) JAK2JAK1JAK3TYK2HSD11B1
SCHEMBL16199903 0.77 JAK1 (0.68) JAK2JAK1JAK3TYK2HSD11B1
SCHEMBL1154788 0.77 JAK1 (0.71) JAK2JAK1JAK3TYK2HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966200-B1 HETEROCYCLIC JANUS KINASE 3 INHIBITORS ASTELLAS PHARMA INC (JP) 2014-10-29 — — EP disclosed
US-20110039822-A1 HETEROCYCLIC JANUS KINASE 3 INHIBITORS ASTELLAS PHARMA INC. (JP) 2011-02-17 — — US disclosed
US-7879844-B2 useful for treating or preventing diseases caused by undesirable cytokine signal transmission such as autoimmune diseases, inflammatory diseases, allergies, transplant rejection, multiple sclerosis, arthritis, psoriasis, asthma, dermatitis, Alzheimer's disease, atherosclerosis, cancer and leukemia ASTELLAS PHARMA INC. (JP) 2011-02-01 — — US disclosed
US-20090270376-A1 HETEROCYCLIC JANUS KINASE 3 INHIBITORS ASTELLAS PHARMA INC. (JP) 2009-10-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039822-A1 HETEROCYCLIC JANUS KINASE 3 INHIBITORS JAK3, JAK1, JAK2 JAK2 3/4885JAK1 2/4885JAK3 1/4885
US-20090270376-A1 HETEROCYCLIC JANUS KINASE 3 INHIBITORS JAK3, JAK1, IRAK3 JAK2 4/4885JAK1 2/4885JAK3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback